The FIDELITY analysis consolidated data from the FIDELIO-DKD and FIGARO-DKD studies, targeting patients with type 2 diabetes across different stages of chronic kidney disease (CKD). This analysis aimed to assess the safety and efficacy of finerenone compared to placebo. Over three years, among 13,026 participants, those treated with finerenone experienced significantly fewer major cardiovascular events and kidney failures than those on placebo.
Findings reveal that finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, effectively reduces cardiovascular and kidney disease progression in type 2 diabetes patients with CKD. The study emphasized the importance of screening for albuminuria to identify at-risk patients, particularly as 40% of participants with a higher estimated glomerular filtration rate were included based on albuminuria. This underscores finerenone’s role in mitigating severe health complications and managing CKD-related cardiovascular risks.
Reference: Agarwal R, Filippatos G, Pitt B, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022 Feb 10;43(6):474-484. doi: 10.1093/eurheartj/ehab777. Erratum in: Eur Heart J. 2022 May 21;43(20):1989. PMID: 35023547; PMCID: PMC8830527.
